PolmanCHReingoldSCBanwellBet al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69: 292–302.
2.
OkudaDT. Unanticipated demyelinating pathology of the CNS. Nat Rev Neurol2009; 5: 591–597.
3.
SatiPOhJConstableRTet al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: A consensus statement from the North American imaging in multiple sclerosis cooperative. Nat Rev Neurol2016; 12: 714–722.
4.
NewtonBDWrightKWinklerMDet al. Three-dimensional shape and surface features distinguish multiple sclerosis lesions from nonspecific white matter disease. J Neuroimaging. Epub ahead of print10May2017. DOI: 10.1111/jon.12449.
5.
TrappBDPetersonJRansohoffRMet al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med1998; 338: 278–285.
6.
FisnikuLKBrexPAAltmannDRet al. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain2008; 131: 808–817.
7.
AzevedoCJOvertonEKhadkaSet al. Early CNS neurodegeneration in radiologically isolated syndrome. Neurol Neuroimmunol Neuroinflamm2015; 2: e102.
8.
OkudaDTSivaAKantarciOet al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS ONE2014; 9: e90509.
9.
KantarciOHLebrunCSivaAet al. Primary progressive multiple sclerosis evolving from radiologically isolated syndrome. Ann Neurol2016; 79: 288–294.
10.
OkudaDFrenayCLSivaAet al. Multi-center, randomized, double-blinded assessment of dimethyl fumarate in extending the time to a first attack in radiologically isolated syndrome (RIS) (ARISE Trial). Neurology2015; 84: 207.
11.
FrenayCLSivaAKantarciOet al. Multi-center, randomized, double-blinded assessment of teriflunomide in extending the time to a first clinical event in radiologically isolated syndrome (RIS) the TERIS study. Neurology2017; 88: 359.
12.
MetzLMLiDKBTraboulseeALet al. Trial of minocycline in a clinically isolated syndrome of multiple sclerosis. N Engl J Med2017; 376: 2122–2133.